EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form
EPA CompTox	DTXSID50887727

Keyword(s):

Human Metabolites

Molecule Category

Free-form

EPA CompTox

DTXSID50887727


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	SGWVAMSJVBTVOB-UHFFFAOYSA-N
Smiles	C1=CC2CC1CC2CP(C)CC3CC4CC3C5C6C=CC(C6)C45
InChI	InChI=1/C22H31P/c1-23(11-18-7-13-2-3-14(18)6-13)12-19-9-17-10-20(19)22-16-5-4-15(8-16)21(17)22/h2-5,13-22H,6-12H2,1H3

InChI Key

SGWVAMSJVBTVOB-UHFFFAOYSA-N

Smiles

C1=CC2CC1CC2CP(C)CC3CC4CC3C5C6C=CC(C6)C45

InChI

InChI=1/C22H31P/c1-23(11-18-7-13-2-3-14(18)6-13)12-19-9-17-10-20(19)22-16-5-4-15(8-16)21(17)22/h2-5,13-22H,6-12H2,1H3

Property Name	Value
Molecular Formula	C22H31P
Molecular Weight	326.22
AlogP	5.4
Hydrogen Bond Acceptor	0.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	0.0
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	23.0

Property Name

Value

Molecular Formula

C22H31P

Molecular Weight

326.22

AlogP

5.4

Hydrogen Bond Acceptor

0.0

Hydrogen Bond Donor

0.0

Number of Rotational Bond

4.0

Polar Surface Area

0.0

Molecular species

None

Aromatic Rings

0.0

Heavy Atoms

23.0

Resources	Reference
CAS NUMBER	70766-51-7
NORMAN SUSDAT

Resources

Reference

CAS NUMBER

70766-51-7

NORMAN SUSDAT


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

[BICYCLO[2.2.1]HEPT-5-EN-2-YLMETHYL](METHYL)[(1,2,3,4,4A,5,8,8A-OCTAHYDRO-1,4:5,8-DIMETHANONAPHTHALEN-2-YL)METHYL]PHOSPHINE

Structure

Physicochemical Descriptors

Cross References